BACKGROUND: Adiponectin shows opposite associations with adverse outcomes in healthy middle-aged populations (lower risk) and cohorts with prevalent cardiovascular disease, heart failure, or advanced age (higher risk). METHODS AND RESULTS: In a population-based study of older adults, we examined the relationships of total and high-molecular-weight adiponectin with mortality among subgroups defined by baseline cardiovascular status: No cardiovascular disease, heart failure, or atrial fibrillation (group 1); cardiovascular disease but no heart failure/atrial fibrillation (group 2); and heart failure/atrial fibrillation (group 3). We found significant differences in the associations with all-cause mortality across the groups. The association in group 1 was U-shaped; increasing levels of total adiponectin up to 12.4 mg/L were associated with lower mortality after adjustment for confounders (hazard ratio=0.81 per 1 SD [95% confidence interval, 0.65-0.95]), but above this cut point, higher levels conferred greater risk (hazard ratio=1.19 [95% confidence interval, 1.12-1.27]). Further adjustment for diabetes mellitus or insulin resistance, protection against which has been proposed to mediate the beneficial relationships of adiponectin with outcome, attenuated the association in the lower range. There was no significant association in group 2, but in group 3, total adiponectin showed a direct adjusted association. Additional adjustment for putative metabolic/inflammatory intermediates suggested a direct association for group 2, and magnified the one for group 3 (hazard ratio=1.31 [1.15-1.50]). Results were similar for high-molecular-weight adiponectin and for cardiovascular mortality. CONCLUSIONS: Adiponectin exhibits distinct associations with mortality in elders, which shift from U-shaped to flat to direct with greater baseline cardiovascular dysfunction but become more consistently adverse after accounting for metabolic/inflammatory factors presumed to be favorably regulated by the adipokine. These findings advance understanding of the adiponectin paradox as it relates to older adults.
BACKGROUND:Adiponectin shows opposite associations with adverse outcomes in healthy middle-aged populations (lower risk) and cohorts with prevalent cardiovascular disease, heart failure, or advanced age (higher risk). METHODS AND RESULTS: In a population-based study of older adults, we examined the relationships of total and high-molecular-weight adiponectin with mortality among subgroups defined by baseline cardiovascular status: No cardiovascular disease, heart failure, or atrial fibrillation (group 1); cardiovascular disease but no heart failure/atrial fibrillation (group 2); and heart failure/atrial fibrillation (group 3). We found significant differences in the associations with all-cause mortality across the groups. The association in group 1 was U-shaped; increasing levels of total adiponectin up to 12.4 mg/L were associated with lower mortality after adjustment for confounders (hazard ratio=0.81 per 1 SD [95% confidence interval, 0.65-0.95]), but above this cut point, higher levels conferred greater risk (hazard ratio=1.19 [95% confidence interval, 1.12-1.27]). Further adjustment for diabetes mellitus or insulin resistance, protection against which has been proposed to mediate the beneficial relationships of adiponectin with outcome, attenuated the association in the lower range. There was no significant association in group 2, but in group 3, total adiponectin showed a direct adjusted association. Additional adjustment for putative metabolic/inflammatory intermediates suggested a direct association for group 2, and magnified the one for group 3 (hazard ratio=1.31 [1.15-1.50]). Results were similar for high-molecular-weight adiponectin and for cardiovascular mortality. CONCLUSIONS:Adiponectin exhibits distinct associations with mortality in elders, which shift from U-shaped to flat to direct with greater baseline cardiovascular dysfunction but become more consistently adverse after accounting for metabolic/inflammatory factors presumed to be favorably regulated by the adipokine. These findings advance understanding of the adiponectin paradox as it relates to older adults.
Authors: Jorge R Kizer; Mary L Biggs; Joachim H Ix; Kenneth J Mukamal; Susan J Zieman; Ian H de Boer; Dariush Mozaffarian; Joshua I Barzilay; Elsa S Strotmeyer; Jose A Luchsinger; Mitchell S V Elkind; W T Longstreth; Lewis H Kuller; David S Siscovick Journal: Am J Epidemiol Date: 2010-12-01 Impact factor: 4.897
Authors: Jorge R Kizer; Alice M Arnold; Nancy S Jenny; Mary Cushman; Elsa S Strotmeyer; Diane G Ives; Jingzhong Ding; Stephen B Kritchevsky; Paulo H M Chaves; Calvin H Hirsch; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2011-06-09 Impact factor: 6.053
Authors: J Poehls; C L Wassel; T B Harris; P J Havel; M M Swarbrick; S R Cummings; A B Newman; S Satterfield; A M Kanaya Journal: Diabetologia Date: 2009-01-22 Impact factor: 10.122
Authors: An M Van Berendoncks; Anne Garnier; Paul Beckers; Vicky Y Hoymans; Nadine Possemiers; Dominique Fortin; Wim Martinet; Viviane Van Hoof; Christiaan J Vrints; Renée Ventura-Clapier; Viviane M Conraads Journal: Circ Heart Fail Date: 2010-01-26 Impact factor: 8.790
Authors: Brian A Bergmark; Christopher P Cannon; William B White; Petr Jarolim; Yuyin Liu; Marc P Bonaca; Faiez Zannad; David A Morrow Journal: Diabetes Obes Metab Date: 2017-03-17 Impact factor: 6.577
Authors: Anne B Newman; Jason L Sanders; Jorge R Kizer; Robert M Boudreau; Michelle C Odden; Adina Zeki Al Hazzouri; Alice M Arnold Journal: Int J Epidemiol Date: 2016-06-06 Impact factor: 7.196
Authors: Gang Liu; Ming Ding; Stephanie E Chiuve; Eric B Rimm; Paul W Franks; James B Meigs; Frank B Hu; Qi Sun Journal: Arterioscler Thromb Vasc Biol Date: 2016-09-08 Impact factor: 8.311
Authors: Fima Macheret; Traci M Bartz; Luc Djousse; Joachim H Ix; Kenneth J Mukamal; Susan J Zieman; David S Siscovick; Russell P Tracy; Susan R Heckbert; Bruce M Psaty; Jorge R Kizer Journal: Heart Date: 2015-04-08 Impact factor: 5.994
Authors: Jason L Sanders; Alice M Arnold; Robert M Boudreau; Calvin H Hirsch; Jorge R Kizer; Robert C Kaplan; Anne R Cappola; Mary Cushman; Mini E Jacob; Stephen B Kritchevsky; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2019-01-01 Impact factor: 6.053
Authors: Joshua F Baker; Anne B Newman; Alka Kanaya; Mary B Leonard; Babette Zemel; Iva Miljkovic; Jin Long; David Weber; Tamara B Harris Journal: J Gerontol A Biol Sci Med Sci Date: 2019-01-16 Impact factor: 6.053
Authors: Michel M Joosten; Kaumudi J Joshipura; Jennifer K Pai; Monica L Bertoia; Eric B Rimm; Murray A Mittleman; Kenneth J Mukamal Journal: Arterioscler Thromb Vasc Biol Date: 2013-02-28 Impact factor: 8.311